SCN ENTERS FOUR NEW EUROPEAN MARKETS
On November 22, 2007, Scandinavian Clinical Nutrition (ticker symbol Oslo Axess and NGM Equity: SCN) signed five new distribution agreements for Immulina® and Coldizin® with sales and marketing partners in Spain, Switzerland, The Netherlands and Belgium. SCN’s products are now sold in 18 markets world-wide.
“The agreements not only represent SCN’s entry into four new markets, but also expose Immulina® and Coldizin® to a new audience of some 75 million consumers, providing potential for additional growth. In line with our previously stated strategies, we are on course to secure similar agreements for additional markets. Today’s announcement shows that we are on the right track”, says Ulf Söderberg, CEO of SCN.
In The Netherlands and Belgium, two distribution agreements have been entered into with a leading distributor for Immulina®, a patented immune system enhancing product, and Coldizin®, a patented product which reduces cold symptoms. Both products will be launched under private labels, expected late 2008.
A third distribution agreement has been secured with an established distributor in Spain, who is part of a global group focusing on sales of nutraceuticals and active pharmaceutical ingredients to pharmaceutical and veterinary industries. The agreement has been entered into for Coldizin®, which will be marketed under private label, containing SCN’s branded ingredient. Launch is expected during the first half of 2008.
Two additional distribution agreements for Immulina® and Coldizin® have been entered into in Switzerland, and launch is predicted for late 2008.
According to the above mentioned agreements, the distributors will be fully responsible for the marketing, sales and distribution in their respective markets, whereas SCN will be providing strategic and technical support.
“Today’s announcement shows that SCN is becoming recognized as a competent provider of innovative nutraceuticals. The international market is very receptive to our products, since they effectively address prominent health issues. With the product pipeline we are developing together with our R&D partners, we believe distributors world-wide will find our proposition attractive”, says Danilo Copiz, VP of Sales at SCN.
With the five new distribution agreements, SCN's products can be found in 18 markets in Europe, Asia, South America and USA. In August, 2007, SCN announced similar distribution agreements with durations from three to five years for eleven countries, including Indonesia, France, Poland, Finland and Denmark. The nutraceutical and food supplement markets are experiencing rapid growth both in Europe and in the rest of the world. In the US alone, the supplement market is estimated at USD 22.5 billion.
With strong ties and relations to renowned research institutions such as Karolinska Institutet in Sweden, University of Mississippi and Johns Hopkins University in the USA, SCN is uniquely positioned in relation to both R&D and the ongoing regulation of the market. A tougher regulatory situation and more educated consumers will be of benefit to companies that can show scientifically documented effects for patent-protected products, and SCN is positioned to do so.
For more information, please contact:
Ulf Söderberg, CEO, us@scnutrition.com, +46 708 13 22 81
Anders Struksnes, Senior Vice President, as@scnutrition.com, +47 911 98 942
Scandinavian Clinical Nutrition AB (publ) works in R&D and sales of scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Membraseven, Coldizin, Immulina and Ledactin. Core competence and strategic alliances within both R&D and sales, in combination with innovative and scientifically documented products, create the right conditions for profitable growth on the international market. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se).